PAI-1 Predicts Quantity of Hepatic Steatosis Independent of Insulin Resistance and Body Weight:
Jeffrey R. Holzberg(Chiricahua Community Health Centers), Miriam B. Vos(Emory University), Thomas R. Ziegler(Emory University), Craig J. McClain(University of Louisville), Ngoc‐Anh Le(Emory University), Ran Jin(Emory University), Gavin E. Arteel(University of Pittsburgh), Juna V. Konomi(Emory University), Elizabeth M. Brunt(Washington University in St. Louis)
Unknown
January 1, 2015
Cited by 1
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Nonalcoholic fatty liver disease
|Nature Reviews Disease Primers|2015|832